Home/Pipeline/JANX011

JANX011

Autoimmune Diseases

Phase 1Active

Key Facts

Indication

Autoimmune Diseases

Phase

Phase 1

Status

Active

Company

Janux Therapeutics

About Janux Therapeutics

Janux Therapeutics is on a mission to transform cancer and autoimmune disease treatment by developing precision-engineered, tumor-activated immunotherapies that maximize efficacy and safety. Founded in 2017, the company has rapidly advanced its proprietary TRACTr and TRACIr platforms, moving multiple programs into clinical development and securing high-value partnerships with Merck and Bristol Myers Squibb. Its strategy centers on solving the critical therapeutic index challenge in immuno-oncology, aiming to expand the utility of potent T-cell redirecting therapies into solid tumors, a vast and underserved market.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Gavocabtagene autoleucel	Astellas	Phase 1/2	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active
I&I Portfolio	Third Arc Bio	Pre-clinical	Active
Undisclosed Platform Programs	Zag Bio	Preclinical	Active
E-602	Palleon Pharmaceuticals	IND-Enabling	Active
DIASPOT Platform Expansion	DIAsource ImmunoAssays	Commercial & Development	Active